Patents by Inventor Torben Leßmann

Torben Leßmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEGylated recombinant human growth hormone compounds
    Patent number: 12274737
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: April 15, 2025
    Assignee: Ascendis Pharma Endocrinology Division A/S
    Inventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
  • PEGylated Recombinant Human Growth Hormone Compounds
    Publication number: 20210220442
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 22, 2021
    Applicant: Ascendis Pharma Endocrinology Division A/S
    Inventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
  • PEGylated recombinant human growth hormone compounds
    Patent number: 10960053
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: March 30, 2021
    Assignee: Ascendis Pharma Endocrinology Division A/S
    Inventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
  • PEGylated Recombinant Human Growth Hormone Compounds
    Publication number: 20190192634
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Application
    Filed: September 28, 2018
    Publication date: June 27, 2019
    Applicant: Ascendis Pharma Endocrinology Division A/S
    Inventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
  • DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS
    Publication number: 20150202317
    Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aliphatic amine group is conjugated to one or more polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.
    Type: Application
    Filed: March 31, 2015
    Publication date: July 23, 2015
    Inventors: Harald Rau, Torben Leßmann